Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma
- PMID: 31987977
- DOI: 10.1016/j.ijrobp.2019.12.036
Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma
Abstract
Purpose: This study aimed to report on the institutional outcomes after proton therapy for pelvic rhabdomyosarcoma (RMS).
Methods and materials: Thirty-one children (≤21 years old) with group III pelvic RMS were enrolled on a prospective outcome study and treated between 2007 and 2018. Patients with vaginal/cervical RMS were excluded. The median age was 2.6 years. Twenty-four patients had embryonal RMS. At diagnosis, the median tumor volume was 185 cm3 and the median maximum diameter was 9.4 cm. Seven patients had N1 disease. Nineteen and 12 patients received European Pediatric Soft Tissue Sarcoma Study Group- and Children's Oncology Group-based chemotherapy, respectively. Fourteen patients underwent resection of the primary tumor after induction chemotherapy, including 6 patients who had a total cystectomy. The median radiation dose was 50.4 Gy relative biological effectiveness.
Results: With a median follow-up of 4.2 years, the 5-year local control, progression-free survival, and overall survival rates were 83%, 80%, and 84%, respectively. Patients <3 years old had better local control (100% vs 68%; P = .02), and patients with embryonal histology had better survival (96% vs 54%; P = .02). No other factors were significantly associated with disease control or survival. Specifically, no statistically significant difference was observed in local control, progression-free survival, or overall survival when comparing patients who underwent biopsy versus gross total resection (75% vs 93%, 68% vs 93%, 75% vs 93%, respectively). Excluding patients who underwent cystectomy, urinary toxicity was limited to 2 patients with nocturnal enuresis. Exploratory surgery to address a persistent mass or thickened bladder wall after radiation was the most common source of serious toxicity.
Conclusions: This cohort of young children with large pelvic tumors treated with proton therapy demonstrates similar local control with less toxicity than historic reports. Functional bladder preservation is possible in most patients. Exploratory biopsy in the 18 months after radiation should be approached with caution.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.Pediatr Blood Cancer. 2019 Nov;66(11):e27952. doi: 10.1002/pbc.27952. Epub 2019 Aug 9. Pediatr Blood Cancer. 2019. PMID: 31397065
-
45 GyRBE for group III orbital embryonal rhabdomyosarcoma.Acta Oncol. 2019 Oct;58(10):1404-1409. doi: 10.1080/0284186X.2019.1627412. Epub 2019 Sep 18. Acta Oncol. 2019. PMID: 31530120
-
Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28. doi: 10.1016/s0360-3016(01)01709-6. Int J Radiat Oncol Biol Phys. 2001. PMID: 11597814 Clinical Trial.
-
Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy.Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1043-1054. doi: 10.1016/j.ijrobp.2019.08.005. Epub 2019 Aug 13. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419513 Review.
-
Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1294-9. doi: 10.1016/s0360-3016(02)04290-6. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654440 Review.
Cited by
-
Clinical Insight on Proton Therapy for Paediatric Rhabdomyosarcoma.Cancer Manag Res. 2023 Oct 10;15:1125-1139. doi: 10.2147/CMAR.S362664. eCollection 2023. Cancer Manag Res. 2023. PMID: 37842128 Free PMC article. Review.
-
Clinical Characteristics, Treatment Considerations, and Outcomes of Infants with Rhabdomyosarcoma.Cancers (Basel). 2023 Apr 14;15(8):2296. doi: 10.3390/cancers15082296. Cancers (Basel). 2023. PMID: 37190224 Free PMC article. Review.
-
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design.Cancers (Basel). 2023 Mar 8;15(6):1660. doi: 10.3390/cancers15061660. Cancers (Basel). 2023. PMID: 36980545 Free PMC article.
-
Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis.Radiat Oncol. 2023 Feb 20;18(1):31. doi: 10.1186/s13014-023-02223-6. Radiat Oncol. 2023. PMID: 36805784 Free PMC article. Review.
-
Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.J Cancer Res Clin Oncol. 2023 Jul;149(7):3161-3170. doi: 10.1007/s00432-022-04209-5. Epub 2022 Jul 25. J Cancer Res Clin Oncol. 2023. PMID: 35879432 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources